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Introduction: The heart and the kidneys are tightly interlinked with each other. So, primary disorder of
one of these organs often results in the secondary dysfunction of other. Such interactions play a vital role
in the pathogenesis of a clinical entity called cardio-renal syndrome (CRS). CRS type 4 refers to the
development of cardiac failure in the patients with CKD.
Objectives: To study the prevalence of various cardiac diseases in the patients with CKD and risk factors
for it.
Methods: Eighty patients with CKD who were being treated at KIMS, Hubli, from 1st January 2015 to
30th June 2015 were selected. Clinical evaluation and relevant investigations including echocardiogra-
phy were done.
Results: Mean age of study population was 43.50  14.53 years. Sex ratio was 50:30 (M:F). Heart failure
with reduced ejection fraction (HFrEF) and Heart Failure with preserved ejection fraction (HFpEF) were
present in 21 (26.25%) and 59 (73.75%) respectively. Left ventricular (LV) hypertrophy was present in
55(68.75%). Thus, the prevalence of CRS type 4 was 61 (76.25%). Pericardial effusion was present in 12 (15%).
Complete heart block was present in 2 (2.5%). Pulmonary hypertension (PH) was present in 35 (43.75%).
Mean central venous pressure (CVP) and interdialysis ﬂuid retention were signiﬁcantly greater among those
with LV failure, compared to those without LV failure (p = 0.0002, p = 0.025 respectively). Mean hemoglobin
was signiﬁcantly lower among patients with LV failure, compared to those without LV failure (p = 0.032).
Conclusion: The prevalence of cardiorenal syndrome type 4 is substantially high in patients with CKD
and carries adverse outcome in relation to patient management.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic kidney disease (CKD) has been increasingly recognized
as a global health problem. More than 10% of the adults in the
United States suffer CKD, of various stages.1 Kidney disease is the
9th leading cause of mortality.2 An Indian population-based study
showed the crude and age-adjusted ESRD incidence rates at
151 and 232 per million population, respectively.3
The patients with CKD most of the times die from cardiovascu-
lar diseases than progressing to End Stage Renal Disease (ESRD).
Cardiovascular diseases such as CAD (coronary artery disease), HF
(heart failure), arrhythmia, and sudden cardiac death represent the
leading causes of morbidity and mortality in the patients with CKD,* Corresponding author.
E-mail address: arunbsmedicine@gmail.com (A. B.S.).
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creativecommons.org/licenses/by-nc-nd/4.0/).increasing sharply as the patients approach ESRD. The pathophys-
iology includes a complex, bidirectional interaction between the
heart and the kidneys and has been termed as cardio-renal
syndrome (CRS) type 4.4
The term ‘cardiorenal syndrome’ has been used to emphasize
the tight interaction between the cardiovascular and the renal
systems in acute or chronic diseases. The deﬁnition encom-
passes different syndromes, all involving the heart and the
kidney, ‘‘whereby an acute or chronic dysfunction of one organ
leads to an acute or chronic dysfunction of the other’’.2 CRS type
4 (also known as chronic renocardiac syndrome) refers to
development of cardiac failure and cardiac complications in
patients with CKD.5,6
There are limited studies reported on CRS type 4. Hence, this
study was conducted in our institute, Karnataka Institute of
Medical Sciences, a Government run Tertiary care center and
Medical college at Hubli, Karnataka.e 4: A study of cardiovascular diseases in chronic kidney disease,
 India. This is an open access article under the CC BY-NC-ND license (http://
Table 1
General characteristics of the patients studied.
Variables Data
1 Age (years)
Mean  S.D. 43.50  14.53
Range 18–70
2 Sex ratio (M:F) 50:30
3 Hypertension 60 (75%)
4 Diabetes mellitus 31 (38.75%)
5 Anemia 76 (95%)
6 CKD stages [No. (%)]
Stage 3 3 (3.75%)
Stage 4 5 (6.25%)
Stage 5 72 (90%)
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1. To know the prevalence of various cardiac diseases in the
patients with CKD.
2. To identify the risk factors for cardiac diseases in CKD.
3. Designs and settings
It was a cross-sectional observational study conducted at
Karnataka Institute of Medical Sciences, from 1st January 2015 to
30th June 2015. Eighty patients with CKD were considered for the
study after explaining the objectives of the study. Informed written
consent was taken from all of them. The study was conducted after
obtaining the approval by the Institute Ethics Committee.
3.1. Inclusion criteria
1. CKD diagnosed based on ‘KDIGO 2012 Clinical Practice Guide-
lines for the Evaluation and Management of CKD’.
2. Those aged 18 years or more.
3.2. Exclusion criteria
1. Those who were not willing to participate in the study.
2. Age less than 18 years.
3. Valvular heart diseases.
4. Congenital heart diseases.
5. Pulmonary obstructive and restrictive diseases.
6. HIV-infected patients.
7. Chronic liver disease.
8. Connective tissue diseases.
9. Hypothyroidism and Hyperthyroidism.
4. Methods
4.1. Protocol
The history was obtained from the patients with CKD, with
special reference to the symptoms of CKD and cardiac disease, risk
factor for developing CKD, co-morbid conditions, duration of
diagnosis of CKD, and duration of hemodialysis. Clinical examina-
tion was done with special emphasis on signs of CKD and cardiac
diseases. Each subject underwent the following investigations:
Renal function tests, liver function tests, serum electrolytes, fasting
plasma glucose, postprandial plasma glucose, complete blood
count, ultrasound abdomen, chest X-ray (CXR), electrocardiogra-
phy (ECG), and echocardiography. Glomerular Filtration Rate (GFR)
was estimated using Cockrault-Gault formula and staging of CKD
was done.
USG abdomen was done to note for the size and echotexture of
the kidney. It was also used to rule out hepatic disease and portal
hypertension as they can independently affect cardiovascular
system. CXR was done to rule out obstructive and restrictive lung
diseases and to look for features suggestive of PH, pulmonary
edema, pleural effusion, cardiomegaly, and pericardial effusion.
ECG was done to assess features of pulmonary hypertension
(PH), right ventricular (RV) strain pattern, left ventricular (LV)
strain pattern, ischemic heart disease (IHD), arrhythmia, and heart
blocks. Echocardiography was done in all patients to evaluate
chamber size, LV systolic dysfunction, LV diastolic dysfunction,
pericardial effusion, and to estimate pulmonary artery systolic
pressure (PASP).
Comparison was made between the two groups.
Group 1: CKD patients with LV failure.
Group 2: CKD patients without LV failure.Please cite this article in press as: H S, et al. Cardiorenal syndrome typ
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clinical features, ECG, and echocardiographic ﬁndings.
4.2. Statistical analysis
Descriptive and inferential statistical analysis had been carried
out in this study. The continuous variables including age, BP, EF,
etc. were expressed in terms of mean  S.D. The categorical
measurements were expressed in number (percentage). Signiﬁcance
was assessed at 5% level of signiﬁcance (p < 0.05).
Student’s t-test (two-tailed, independent) was used to ﬁnd the
signiﬁcance of the study parameters on continuous scale between
the two groups with presence and absence of LV failure (Inter
group analysis) on metric parameters. Chi-square/Fisher Exact test
was used to ﬁnd the signiﬁcance of study parameters on
categorical scale between the two groups. Statistical analysis
was done with the IBM SPSS version 20.
5. Results
5.1. General characteristics
Mean age of the study population was 43.50  14.53 years
(mean  S.D.). Majority were of the age 31 years to 50 years (65%),
which represents the productive age group of the society. Majority of
the patients were in stage 5 CKD (Table 1).
5.2. Clinical ﬁndings
Breathlessness was the commonest symptom, which was
present in 68 out of 80 patients (85%). Pedal edema was present
in 65 out of 80 patients (81.25%) (Fig. 1).
Systolic hypertension and diastolic hypertension were present
in 60 (75%) and 52 (65%) respectively (Table 2, Table 3).
5.3. Cardiac manifestations in CKD
HFrEF was present in 21 (26.25%) patients. HFpEF was present
in 59 (73.75%) patients. Total prevalence of left heart failure was 61
(76.25%) patients, with HFpEF being more common than HFrEF.
LV hypertrophy was present in 55(68.75%) patients. PH was
present in 35(43.75%) patients. Pericardial effusion was present in
12 (15%) patients (Table 4, Fig. 2). All the cardiac complications
were predominantly seen in CKD stage 5 (Table 5).
Among patients with HFrEF, majority had mild LV systolic
dysfunction – 17 (21.25%) (Table 6).
5.4. Pulmonary hypertension
Pulmonary hypertension (PH) was present in 35(43.75%).
Majority of the patients had moderate PH. In CKD stage 3, it
was present in 1 out of 3 (33.3%). In stage 4, it was present in 2 oute 4: A study of cardiovascular diseases in chronic kidney disease,
Fig. 1. Prevalence of various clinical ﬁndings in the patients studied.
Table 2
SBP in the patients studied.
Grading of SBP SBP (mm Hg) Total (n = 80)
Normal <120 3 (3.75%)
Prehypertension 120–139 17 (21.25%)
Stage 1 hypertension 140–159 20 (25%)
Stage 2 hypertension 160 40 (50%)
Table 3
DBP in the patients studied.
Grading of DBP DBP (mm Hg) Total (n = 80)
Normal <80 13 (16.25%)
Prehypertension 80–89 15 (18.75%)
Stage 1 hypertension 90–99 8 (10.0%)
Stage 2 hypertension 100 44 (55.0%)
Table 4
Echocardiographic ﬁndings in the patients studied.
ECHO ﬁndings No. of patients (%)
HFrEF 21 (26.25%)
HFpEF 59 (73.75%)
LV hypertrophy 55 (68.75%)
PH 35 (43.75%)


















Fig. 2. Echocardiographic ﬁndings in the patients studied.
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Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.07.006of 5 patients (40%). In stage 5, it was present in 32 out of 72 patients
(44. 44%). This shows that with the progression of CKD, prevalence
of PH also increases, although it is not statistically signiﬁcant
(p = 0.716) (Table 7).
5.5. Comparison between two groups
Clinical features such as breathlessness, pedal edema, and
pulmonary edema were signiﬁcantly more common among those
with LV failure compared to those without LV failure (Table 8).
In ECG, the prevalence of left ventricular strain pattern and right
ventricular strain pattern was signiﬁcantly more among the patients
with LV failure, compared to those without LV failure (Table 9).Table 5
Comparison of echocardiographic ﬁndings in different stages of CKD.
Echocardiographic ﬁndings Stages of CKD
3 (n = 3) 4 (n = 5) 5 (n = 72)
LV hypertrophy 0 2 (40%) 53 (73.61%)
HFrEF 0 1 (20%) 20 (27.78%)
HFpEF 1 (33.33%) 2 (40%) 56 (77.78%)
Pericardial effusion 0 0 12 (16.66%)
Table 6
Grading of HFrEF based on EF in the patients studied.
Grading of HFrEF EF (%) No. of patients (%)
Normal 55 59 (73.75%)
Mild 45–54 17 (21.25%)
Moderate 30–44 4 (5%)
Severe <30 0 (0%)
Table 7
PH in different stages of CKD.
PH grades PASP (mm Hg) Stage of CKD Total
3 4 5
Absent <35 2 3 40 45
Mild 35–49 1 1 14 16
Moderate 50–69 0 1 17 18
Severe 70 0 0 1 1
Total 3 5 72 80
e 4: A study of cardiovascular diseases in chronic kidney disease,
Table 8
Comparison of clinical features between the patients with presence and absence of
LV failure.





Breathlessness 59 9 68 0.0001*
Fatigue 40 8 48 0.106
Chest pain 10 1 11 0.444
Pedal edema 56 9 65 0.0001*
Pleural effusion 14 3 17 0.749
Pulmonary edema 35 2 37 0.004*
* Statistically signiﬁcant at p > 0.05.
Table 9
ECG ﬁndings in relation to presence or absence of LV failure.





P pulmonale 1 0 1 1
Left ventricle strain 50 2 52 0.014*
Ischemic heart diseasea 4 0 4 0.56
Right ventricular strain 13 0 13 0.030*
Complete heart block 2 0 2 1
a IHD was diagnosed based on present and past ECG and echo records. Invasive
modes like Coronary angiography were not done in them.
* Statistically signiﬁcant at p > 0.05.
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LV failure compared to those without LV failure (p = 0.0013 and
p = 0.0036 respectively). This implies that the pressure overload is
associated with increased risk of LV failure (Table 10).
Mean  S.D. of CVP and interdialysis weight gain were signiﬁcantly
higher among the patients with LV failure compared to those without
LV failure (p = 0.0002 and p = 0.05 respectively). This implies that the
volume overload is associated with increased risk of LV failure
(Table 10).
Duration of CKD and hemodialysis was longer among the
patients with LV failure compared to those without LV failure, but
it was not statistically signiﬁcant.
Mean  S.D. of hemoglobin among the patients with LV failure
(7.01  1.78) was signiﬁcantly lower as compared to those without
LV failure (p = 0.032). This implies that anemia is associated with
increased risk of LV failure in CKD patients (Table 10).
6. Discussion
CKD patients have higher mortality, when compared to the
general population, which is mainly attributed to cardiovascularTable 10
Comparison of the characteristics between the groups with presence and absence of L
LV failure 
Present (n = 61) 
Age in years 44.09  15.2 
Pulse rate (bpm) 90.37  13.24 
SBP (mm Hg) 160.24  24.89 
DBP (mm Hg) 94.88  13.68 
CVP (cm H20) 22.31  7.12 
Interdialysis weight gain (kg) 3.11  1.47 
CKD duration (weeks) 47.01  68.61 
Hemoialysis duration (weeks) 28.87  46.80 
Hemoglobin (g/dl) 7.47  2.09 
* Statistically signiﬁcant at p > 0.05.
Please cite this article in press as: H S, et al. Cardiorenal syndrome typ
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than progressing to ESRD and the need of renal replacement
therapy.7
Proteinuria, whether considered as a marker of systemic
endothelial dysfunction or a result of renal damage, has been
associated with increased cardiovascular mortality.8 In repeated
studies, the presence of micro- and macroalbuminuria and GFR
reduction were independent predictors of increased overall and
cardiovascular mortality in both diabetic patients and non-diabetic
patients.9,10
Irrespective of the presence of proteinuria, decline in GFR has
been associated with increased cardiovascular morbidity and
mortality. An inverse relationship between GFR and the severity of
coronary artery stenosis was found as well as increased probability
of having triple vessel disease with decreasing GFR.11
6.1. Pathogenesis of cardiorenal syndrome type 4
Several pathophysiological pathways have been identiﬁed to
cause CRS type 4, including Renin-Angiotension-Aldosterone
system (RAAS) activation, volume overload, osmotic sodium
retention, endothelial dysfunction, anemia, dyslipidemia, coagulo-
pathy, inﬂammation,12 all leading to morphological alterations in
the heart and vessels. In addition, other proposed mechanisms
include sympathetic overactivity, non-osmotic sodium retention,
cardiotonic steroids, and catalytic iron. Sympathetic activation by
the failing kidney leads to both renal disease progression and
cardiovascular morbidity.12
Risk factors for LV failure in CKD are traditional risk
factors like hypertension, diabetes mellitus, hypercholesterol-
emia, age, smoking, obesity, and male sex.13,14 Apart from
these, non-traditional factors that have been implicated
are anemia, inﬂammation, oxidative stress, endothelial dysfunc-
tion, circulating soluble receptor for advanced glycation end
product (sRAGE), altered mineral metabolism, hyperparathy-
roidism, Fibroblast Growth Factor 23, asymmetric dimethyargi-
nine, e-selectin, albuminuria, hyperuricemia, and arterial
stiffness.14
A study by Joachim H. Ix et al. showed that higher serum
cystatin C concentrations are strongly associated with LV
hypertrophy and diastolic dysfunction.15
Vitamin D deﬁciency is quite prevalent among CKD patients,
and it is associated with the high prevalence of myocardial
dysfunction, heart failure, and sudden cardiac death.16
Nerpin et al. described the association between GFR and LV
function in two independent community-based cohorts with no
clinical evidence of heart failure, LV EF >40% and with GFR
>60 mL/min per 1.73 m2. The investigators observed a signiﬁcant
correlation between GFR and systolic, diastolic, and global LV
function in both the studies.17V failure.
Total (n = 80) p value
Absent (n = 19)
42.33  11.20 43.50  14.53 0.643
90.17  4.87 90.34  12.33 0.949
136.17  34.35 157.43  26.62 0.0013*
84.17  13.14 93.88  13.73 0.0036*
15.33  5.47 20.53  7.07 0.0002*
2.26  1.22 2.81  1.43 0.025*
24.33  32.35 43.57  64.79 0.169
12  14.23 26.30  43.80 0.127*
8.6  1.5 7.71  2.04 0.032*
e 4: A study of cardiovascular diseases in chronic kidney disease,
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LV hypertrophy is a common feature in CKD patients. It is
attributable to both pressure overload and volume overload.
Pressure overload is mainly derived from the increased peripheral
vascular resistance and reduced arterial compliance due to
sympathetic and RAAS overactivity, hypertension, endothelial
dysfunction, and vascular calciﬁcation/stiffening. It causes thick-
ening of cardiac myoﬁbres by parallel addition of sarcomeres, thus
leading to concentric LV hypertrophy.18
Volume overload is attributed to sodium and water retention,
anemia, and the presence of an arteriovenous ﬁstula in patients
with ESRD.18
LV hypertrophy in renal disease is a pathologic process and is
accompanied by ﬁbrosis, which is also attributed to metabolic
consequence of uremia, including increased parathyroid hormone,
endothelin, aldosterone, catecholamines, and cardiotonic ster-
oids.10 Other histological changes of the heart in CKD include
myocyte apoptosis/necrosis resulting in myocyte number reduc-
tion, and microvascular abnormalities such as arteriolar wall
thickening and capillary rarefaction, the latter being speciﬁc to
uremia.4
The consequences of above-mentioned structural changes
include diastolic dysfunction, increased oxygen demand, and
impaired myocardial oxygenation unrelated to coronary artery
obstruction. This may explain the angiographic ﬁnding of patent
coronary arteries in 30–40% of CKD patients with IHD.19 These
changes also explain their predisposition to arrhythmias and
sudden death, which account for more than half of the
cardiovascular mortality in them.20 Susceptibility to arrhythmias
and sudden death may be further increased by CAD/MI, CHF, LV
hypertrophy, electrolyte abnormalities, anemia, autonomic imbal-
ance, and inﬂammation.20
6.3. Vascular changes in CKD
Pathological features in CKD include thickening of the arterial
wall, leading to an increased intima-media thickness and, vascular
calciﬁcation.21,22. This leads to increased arterial pulse wave
velocity.23 Quite recently, the vascular calciﬁcation has become the
focus of attention mainly because of its established association
with cardiovascular mortality in CKD patients.24
6.4. LV failure in CKD
Avijit Debnath et al. have done an echocardiographic assess-
ment of CKD patients. The assessment showed that 30% of total
patients had LV systolic dysfunction, 15% among the patients with
CKD stages 1–3, and 48% among the patients with CKD stages 4–5.
LV hypertrophy was present in 58% among total study population,
being prevalent in 33% and 87% among CKD stages 1–3 and stages
4–5 respectively.25
In comparison with the above study, in our study also, HFrEF
(LV systolic dysfunction) was present in 26.25% of patients. HFpEF
(LV diastolic dysfunction) was present in 77.75% of patients and LV
hypertrophy in 68.75% of patients. In consistent with the above
study, our study also shows that LV failure to be a predominant
complication of ESRD.
In CKD patients, LV hypertrophy contributes to diastolic
dysfunction, congestive heart failure, arrhythmia, and sudden
death.26 The prevalence of LV hypertrophy in the general
population is 15–21%,27 but it affects 50–70% of patients
during intermediate stages of CKD and up to 90% of
patients with ESRD.28–30 In our study, LV hypertrophy was
present in 40% of CKD stage 4 patients and 73.61% of CKD stage
5 patients.Please cite this article in press as: H S, et al. Cardiorenal syndrome typ
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It is one of the overlooked complications of CKD, which has been
estimated to be present in 27–58% of CKD patients in various
studies.31–35 It is an independent predictor of morbidity and
mortality in them.32,34
In the ﬁrst study of PH in CKD patients conducted by Yigla et al.,
the prevalence of PH in CKD patients was 39.7% and risk factors for
developing PH were anemia and increased cardiac output.31
Kumbar et al. found the prevalence of 42% in 36 patients of
peritoneal dialysis and risk factors identiﬁed were dilated LV,
lower EF and increased calcium phosphate product. Fabbian et al.
in their study found the prevalence of PH in 58.6% of patients on
hemodialysis and 18.5% of peritoneal dialysis patients. All these
studies demonstrate that LV failure is the predominant cause of PH
in these patients, causing WHO group 2 PH.32
In consistent with these studies, PH was present in 43.75% of the
patients in our study.
6.6. Anemia in CKD
Anemia is very common in CKD and contributes to cardiovas-
cular disease. Various factors responsible for anemia, which
include erythropoietin deﬁciency, diminished red cell survival,
deﬁciency of iron, Vitamin B12 and folate due to malabsorption and
anorexia, impaired coagulation and platelet function due to
uremia, hyperparathyroidism, bone marrow ﬁbrosis, and chronic
inﬂammation.36
Robinson et al. conducted the study on prevalence of anemia
nursing home residents and concluded that 59.6% of residents
were anemic, and 43.1% had CKD, and residents with CKD were
more likely to have anemia (64.9% with CKD vs 55.7% without
CKD).37 In our study, anemia had very high prevalence of 95%
among CKD patients.
7. Conclusion
This study concludes that substantial number of patients with
CKD suffers cardiovascular disease, i.e., Cardiorenal syndrome-
type 4. HFpEF is more common than HFrEF. The risk factors for LV
failure are anemia, volume overload secondary to ﬂuid retention,
and pressure overload secondary to systemic hypertension.
Pulmonary hypertension is one of the recently recognized
complications of CKD which is often overlooked. All these
cardiovascular manifestations independently contribute to ad-
verse outcome in these patients.
The high prevalence of LV failure on echocardiography implies
that these patients require detailed cardiovascular evaluation
despite absence of symptoms. Efforts targeted at prevention and
control of LV failure and PH such as control of systemic
hypertension, control of diabetes mellitus, correction of anemia,
identiﬁcation and treatment of IHD, achieving dry weight by
setting an optimum ultraﬁtrate at hemodialysis, and optimal use of
diuretics should be implemented as early as possible, to improve
the treatment outcome of these patients.
8. Limitations of the study
1. The patients could not be followed up.
2. Impact of hemodialysis and correction of risk factors like
anemia, systemic hypertension, diabetes mellitus, and volume
overload on cardiac function could not be assessed.
Conﬂicts of interest
The authors have none to declare.e 4: A study of cardiovascular diseases in chronic kidney disease,
S. H. et al. / Indian Heart Journal xxx (2016) xxx–xxx6
G Model
IHJ-1010; No. of Pages 6References
1. Centers for Disease Control and Prevention. National chronic kidney disease fact
sheet: general information and national estimates on chronic kidney disease in the
United States. Atlanta, GA: US Department of Health and Human Services, Centers
for Disease Control and Prevention; 2014.
2. Centers for Disease Control and Prevention. Leading causes of death. 2013.
3. Modi G, Jha V. Incidence of ESRD in India. Kidney Int. 2011;79:573.
4. Pateinakis P, Papagianni A. Cardiorenal syndrome type 4—cardiovascular disease in
patients with chronic kidney disease: epidemiology, pathogenesis, and manage-
ment. Int J Nephrol. 2011;2011:8938651. http://dx.doi.org/10.4061/2011/938651.
5. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the
consensus conference of the acute dialysis quality initiative. Eur Heart J.
2010;31:703–711.
6. House AA, Anand A, Bellomo R, et al. Deﬁnition and classiﬁcation of Cardio-Renal
Syndromes: workgroup statements from the 7th ADQI Consensus Conference.
Nephrol Dial Transplant. 2010;25:1416–1420.
7. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes
among a population with chronic kidney disease in a large managed care organi-
zation. Arch Intern Med. 2004;164(March (6)):659–663.
8. Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular
disease: analysis of potential mechanisms. JASN. 2006;17(8):2106–2111.
9. Ninomiya T, Perkovic V, De Galan BE, et al. Albuminuria and kidney function
independently predict cardiovascular and renal outcomes in diabetes. JASN.
2009;20(8):1813–1821.
10. Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular ﬁltration rate,
albuminuria, and risk of cardiovascular and all-cause mortality in the US popula-
tion. Am J Epidemiol. 2008;167(10):1226–1234.
11. Weber-Mzell D, Kotanko P, Schumacher M, et al. Coronary anatomy predicts
presence or absence of renal artery stenosis: a prospective study in patients
undergoing cardiac catheterization for suspected coronary artery disease. Eur
Heart J. 2002;23(21):1684–1691.
12. McCullough PA. Why is chronic kidney disease the ‘‘spoiler’’ for cardiovascular
outcomes? J Am Call Cardiol. 2003;41(5):725–728.
13. Kasiske BL. The kidney in cardiovascular disease. Ann Intern Med. 2001;134:
707–709.
14. Campese VM. Left ventricular function and chronic kidney disease. How soon does
start? Nephrol Dial Transplant. 2014;29(11):1989–1991.
15. Ix JH, Shlipak MG, Chertow GM, et al. Cystatin C, left ventricular hypertrophy, and
diastolic dysfunction: data from the Heart and Soul Study. J Card Fail. 2006;12:
601–607.
16. Pilz S, Ma¨rz W, Wellnitz B, et al. Association of vitamin D deﬁciency with heart
failure and sudden cardiac death in a large cross-sectional study of patients
referred for coronary angiography. Clin Endocrinol Metab. 2008;93:3927–3935.
17. Nerpin E, Ingelsson E, Rise´rus U, et al. The association between glomerular
ﬁltration rate and left ventricular function in two independent community-based
cohorts of elderly. Nephrol Dial Transplant. 2014;29:2069–2074.Please cite this article in press as: H S, et al. Cardiorenal syndrome typ
Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.07.00618. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular
system. JASN. 2006;17(8):2112–2119.
19. Losi MA, Memoli B, Contaldi C, et al. Myocardial ﬁbrosis and diastolic dysfunction
in patients on chronic haemodialysis. Nephrol Dial Transplant. 2010;25(6):
1950–1954.
20. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients.
Semin Dial. 2008;21(4):300–307.
21. Mizobuchi M, Towler D, Slatopolsky E. Vascular calciﬁcation: the killer of patients
with chronic kidney disease. JASN. 2009;20(7):1453–1464.
22. McCullough PA, Agarwal M, Agrawal V. Risks of coronary artery calciﬁcation in
chronic kidney disease: do the same rules apply? Nephrology. 2009;14(4):
428–436.
23. Blacher J, Guerin AP, Pannier B, et al. Arterial calciﬁcations, arterial stiffness, and
cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–942.
24. Ohya Y, Iseki K, Iseki C, et al. Increased pulse wave velocity is associated with low
creatinine clearance and proteinuria in a screened cohort. Am J Kidney Dis.
2006;47(5):790–797.
25. Debnath A, Chaudhury SR, Chaturvedi AN, et al. Echocardiographic assessment of
left ventricular systolic dysfunction in chronic kidney disease patients of a rural
tertiary medical care centre in West Bengal. IOSR-JDMS. 2014;13(1):69–73.
26. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic value of echocardiographic
indicators of left ventricular systolic function in asymptomatic dialysis patients. J
Am Soc Nephrol. 2004;15:1029–1037.
27. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiogra-
phically determined left ventricular mass in the Framingham Heart Study. N Engl J
Med. 1990;322:1561–1566.
28. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in
patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192.
29. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy
in and survival of patients receiving hemodialysis: follow-up of an interventional
study. J Am Soc Nephrol. 2001;12:2759–2767.
30. Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic
predialysis CKD. Am J Kidney Dis. 2005;46:320–327.
31. Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-
stage renal disease. Chest. 2003;123:1577–1582.
32. Andrew M, Meghan E, Richard N. Pulmonary hypertension in patients with chronic
and end-stage kidney disease. Kidney Int. 2013;84:682–692.
33. Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J
Kidney Dis. 2013;61(4):612–622.
34. Kumbar L, Fein PA, Raﬁq MA, et al. Pulmonary hypertension in peritoneal dialysis
patients. Adv Perit Dial. 2007;23:127–131.
35. Fabbian F, Cantelli S, Molino C, et al. Pulmonary hypertension in dialysis patients: a
cross-sectional Italian study. Int J Nephrol. 2011283475.
36. Babitt J, Lin HY. Mechanisms of Anemia in CKD. JASN. 2012;23(October):
1631–1634.
37. Artz AS, Culleton B. Prevalence of anemia in the nursing home: contribution of
chronic kidney disease. J Am Geriatr Soc. 2007;(October (10)):1566–1570.e 4: A study of cardiovascular diseases in chronic kidney disease,
